Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;41(7):677-683.
doi: 10.1007/s40264-018-0646-2.

Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors

Affiliations

Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors

Corine Ekhart et al. Drug Saf. 2018 Jul.

Abstract

Introduction: Several studies have investigated sex as a risk factor for the occurrence of adverse drug reactions (ADRs) and found that women are more likely to experience ADRs than men.

Objective: The aim of this explorative study was to investigate whether differences exist in reported ADRs of selective serotonin reuptake inhibitors (SSRIs) for men and women in the database of the Netherlands Pharmacovigilance Centre Lareb.

Methods: A ratio of reports concerning women and men, corrected for the number of users, was calculated for all the ADRs reported on SSRIs.

Results: We found that 16 ADRs were statistically significantly more reported in women than men, and four ADRS were reported more in men than women.

Conclusion: ADRs more reported in women than men when using SSRIs were usually dose-related ADRs or commonly occurring ADRs. Differences in the pharmacokinetics of SSRIs between men and women may explain why these reports of dose-related ADRs when using SSRIs concern women more than men.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharmacokinet. 1997;32 Suppl 1:22-30 - PubMed
    1. Clin Pharmacol Ther. 1981 Aug;30(2):239-45 - PubMed
    1. Ther Drug Monit. 2003 Apr;25(2):183-91 - PubMed
    1. Br J Clin Pharmacol. 2011 Jan;71(1):95-104 - PubMed
    1. Drug Saf. 2001;24(8):575-85 - PubMed

MeSH terms

Substances

LinkOut - more resources